Detalhe da pesquisa
1.
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
J Eur Acad Dermatol Venereol
; 37(12): 2517-2525, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37625815
2.
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Dermatol Ther
; 35(2): e15231, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34820971
3.
Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study.
Dermatol Ther
; 35(11): e15831, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36109488
4.
The AGEs of Psoriasis: A Biomarker for Severity and a Pathogenetic Link to Comorbidities.
Acta Derm Venereol
; 97(7): 775, 2017 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28681911
5.
ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
J Am Acad Dermatol
; 74(6): 1066-72, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27004803
6.
Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.
Patient Prefer Adherence
; 17: 1541-1549, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37408843
7.
Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
Dermatology
; 225(1): 14-7, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22890275
8.
Psoriatic arthritis. / Artritis psoriásica.
Med Clin (Barc)
; 159(1): 40-46, 2022 07 08.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-35525675
9.
A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
Int J Clin Pharm
; 44(3): 725-730, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35380392
10.
Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.
J Dermatolog Treat
; 31(3): 222-226, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30883242
11.
Biosimilars for the treatment of psoriasis.
Expert Opin Biol Ther
; 19(10): 993-1000, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31237786
12.
Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain.
J Dermatolog Treat
; 30(5): 424-429, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30244618
13.
Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service.
J Dermatolog Treat
; 28(7): 623-630, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28784002
14.
Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group.
J Dermatolog Treat
; 33(6): 2878-2880, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35593480
15.
Pityriasis lichenoides chronica induced by infliximab, with response to methotrexate.
Eur J Dermatol
; 20(4): 511-2, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20395191
16.
Secukinumab (AIN457) for the treatment of psoriasis.
Expert Rev Clin Immunol
; 11(11): 1177-88, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26428036
17.
Differences in the O-glycosylation patterns between lung squamous cell carcinoma and adenocarcinoma.
Am J Clin Pathol
; 118(5): 749-55, 2002 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-12428796
18.
Artritis psoriásica / Psoriatic arthritis
Med. clín (Ed. impr.)
; 159(1): 40-46, julio 2022.
Artigo
em Espanhol
| IBECS (Espanha) | ID: ibc-206289
19.
Pityriasis rubra pilaris triggered by photodynamic therapy with response to tumor necrosis factor α-blocking agents and acitretin.
Cutis
; 93(3): E6-7, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24738108
20.
Changes in the invasive and metastatic capacities of HT-29/M3 cells induced by the expression of fucosyltransferase 1.
Cancer Sci
; 98(7): 1000-5, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17459061